Tag: IPO

Facebook Shares will change the world many ways

Facebook’s IPO did not mark the stock market as per investors’ expectation, but on the first day of trading company shares end on a low of $38.23 and raised as much as $18.4 billion in one of the biggest initial public offerings in U.S. history.

The eight-year-old social network site’s share value rose up 11 per cent and rose to $45 in starting and after that fall down at $38.23, 16% above the company’s initial pricing of $38. Read more

MCX IPO gets 91% subscription on first day

The latest news from the business state, the first initial public offer (IPO) of the 2012 opened yesterday and has received a high response.

It is said in reports that the Multi Commodity Exchange (MCX) IPO was almost fully subscribed on day one itself.

MCX IPO got more than 91 percent of subscriptions. While it’s price band is ranked from Rs 860 to Rs 1,032 per share.

Further, the bidding for the shares through the IPO will close on February 24. The MCX IPO has seen total subscription of 0.9X, of which 0.74X came from qualified foreign investors (QFI). Its non-institutional investors (NIIs) added 0.16, and 1.5 subscriptions were from retail. Read more

Piramal acquires more 5.5% stake in Vodafone

vodafone 300x238 Piramal acquires more 5.5% stake in VodafonePiramal Healthcare firm has decided to buy an additional 5.5% stake in Vodafone India whose cost will be Rs3,007 crore.

Piramal firm already bought 5.5% stake of Vodafone for Rs2,900 crore in August last year and its further plan to buy will values Vodafone’s India business at Rs54,675 crore.

However these days, Vodafone has several beneficial facts in which one is its rejoice moment is of won the long-drawn out tax war for Rs11,000 crore against the I-T department.

Piramal Healthcare has values at Rs10,000 crore and its plan to buy Vodafone’s stake would offers various exit mechanisms for Piramal, including through participation in a potential IPO and sale of stake to Vodafone. Read more

Advertise With Us || Contact Us || Priyacy Policy || Disclaimer || About Us || Our Editors